# Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

> **NCT04733963** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 112 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib Plus Capecitabine
- **DRUG:** Bevacizumab Plus Capecitabine

## Key facts

- **NCT ID:** NCT04733963
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04733963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04733963, "Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04733963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*